GlobeNewswire by notified

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Share

Company Announcement

COPENHAGEN, Denmark; November 14, 2022Genmab A/S (Nasdaq:GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:
Marisol Peron, Senior Vice President, Communications and Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-Fand other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.



CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Mandalay Resources Corporation Announces Refinancing of Credit Facility2.12.2022 02:26:55 CET | Press release

Not for distribution to U.S. news wire services or dissemination in the United States. TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to announce that it has entered into a credit agreement with The Bank of Nova Scotia (“Scotiabank”) providing for a senior secured revolving credit facility in an aggregate amount of up to US$35 million (the “Revolving Credit Facility”). The initial drawdown under the Revolving Credit Facility will be used to repay the Company’s existing syndicated facility with HSBC Bank Canada and Macquarie Bank Limited (the “Existing Facility”) which had US$32.6 million outstanding before repayment. The residual proceeds from the Revolving Credit Facility will be used for general corporate and working capital purposes. The hedge arrangements entered into in connection with the Existing Facility will remain in place until their expiry in June 2023. The Revolving Credit Facility

Bond launches brand in Europe. Continuing to build new growth for clients across the globe2.12.2022 00:05:15 CET | Press release

Following the integration of recently acquired Buljan & Partners, Bond formally brings its purpose of championing growth to Europe and beyond TORONTO and MADRID, Spain, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Bond, a leading customer experience, loyalty, and growth firm, officially launched the Bond brand in Europe with a client event in Madrid followed by a road show of client presentations in Barcelona, Munich, Cologne and Hamburg. With an extensive footprint in Europe, Middle East and Africa (EMEA), the region will be led by Silvana Buljan, Executive Director of Bond, and founder of Buljan & Partners, acquired by Bond earlier in 2022. “Our business is built on a shared belief that human-centric brands are best positioned to develop tech-enabled connections, enduring relationships, and powerful bonds that drive unmatched growth,” said Buljan. “Since joining Bond in May, we have effectively combined the strength of both organizations to add greater value to the world-class brands we serve.

Alvotech Announces Changes to its Leadership Team1.12.2022 23:00:00 CET | Press release

Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become CEO Changes to the leadership team are effective January 1, 2023 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its leadership team. Mark Levick, Chief Executive Officer has decided to step down and Robert Wessman, Executive Chairman and founder will become CEO, leading the next phase of growth. Hafrun Fridriksdottir, previously Executive Vice President and Head of Global R&D at Teva, has been appointed Chief Operating Officer. Changes to the leadership team are effective January 1, 2023. “We continue positioning Alvotech for growth, as we transition from R&D and building an end-to-end biosimilars platform, to the next phas

Constellation Brands to Report Third Quarter Fiscal 2023 Financial Results; Host Conference Call January 5, 20231.12.2022 22:30:00 CET | Press release

VICTOR, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its third quarter ended November 30, 2022, on Thursday, January 5, 2023, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Financial Officer, Garth Hankinson, at 10:30 a.m. ET, January 5, 2023. The conference call can be accessed by dialing +1-877-407-9121 and entering conference identification number 13734749, beginning at 10:20 a.m. ET. A live, listen-only webcast of the conference call will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the call begins, financial information discussed on the conference call, and a reconciliation of reported GAAP financial measures with comparable or non

Leading Global Operator Selects Synchronoss to Deliver Personal Cloud Offering1.12.2022 22:16:14 CET | Press release

Leading Provider of Mobile, Telecommunications and ISP Services Rolling Out Personal Cloud Offering to Safeguard Files, Photos, Videos, and Other Digital Content BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced a multi-year agreement with one of the largest global operators to deploy Synchronoss Personal Cloud to tens of millions of subscribers on its network. This agreement will contribute to Synchronoss’s financial results this quarter, as deployment preparations are underway, and transition into primarily a SaaS-based revenue model as subscribers adopt the service. As one of the world’s top providers of mobile devices and communications services, this international customer is partnering with Synchronoss to offer an array of value-added services, including the ability to backup and manage files, phot